Der p 1 is one of the major allergenic molecules of Dermatophagoides pteronyssinus, causing house dust mite (HDM)
allergy. The pathological B cells produce
allergen-specific
IgE antibodies that mediate the
hypersensitivity reaction, therefore the selective elimination of these B cells is a legitimate therapeutic goal in
allergy. Chimeric molecule Dp51-72 able to cross-link B cell inhibitory
complement receptor type 1 and BCR on Der p 1-specific B cells was constructed. The signalling capabilities of this molecule have been tested on human B cells. A humanized mouse model of HDM
allergy has been used to test the in vivo effects of the chimeric molecule administration. Administering the chimeric molecule to immunodeficient Rag2- γc- mice transferred with PBMCs from allergic patients resulted in reduction of
allergen-specific
IgE antibodies in the sera, and reduced infiltration of immune cells in lung histology preparations. Reduced numbers of human CD45+ and CD4+ cells in the lungs as well as inhibition of mast cell degranulation were also observed. The treatment with Dp51-72 chimera significantly decreased the local levels of anti-Dpt
IgE antibodies in the bronchoalveolar lavage fluid (BALF). The binding of the chimeric molecule to tonsillar B cells triggers the
tyrosine phosphorylation of 30-32 kDa
protein, which is most likely involved in the inhibitory process. Administration of constructed chimeric molecules to humanized mice with developed
inflammation resulted in specific suppression of disease-associated
IgE antibody-producing cells and preserved lung histology. This effective approach could be further developed into a therapeutic agent for treatment of patients with HDM
allergy.